148 related articles for article (PubMed ID: 36290285)
1. Quantification of Carbonic Anhydrase Inhibitors and Metabolites in Urine and Hair of Patients and Their Relatives.
Lo Faro AF; Tini A; Bambagiotti G; Pirani F; Faragalli A; Carle F; Pacella E; Ceka A; Moretti M; Gottardi M; Lassandro NV; Nicolai M; Lupidi M; Mariotti C; Busardò FP; Carlier J
Biology (Basel); 2022 Sep; 11(10):. PubMed ID: 36290285
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a fast ultra-high-performance liquid chromatography tandem mass spectrometry method for determining carbonic anhydrase inhibitors and their metabolites in urine and hair.
Lo Faro AF; Tini A; Gottardi M; Pirani F; Sirignano A; Giorgetti R; Busardò FP
Drug Test Anal; 2021 Aug; 13(8):1552-1560. PubMed ID: 33908166
[TBL] [Abstract][Full Text] [Related]
3. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
Kadam RS; Jadhav G; Ogidigben M; Kompella UB
Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
[TBL] [Abstract][Full Text] [Related]
4. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Gugleta K
Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
[TBL] [Abstract][Full Text] [Related]
5. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting.
Barnebey H; Kwok SY
Clin Ther; 2000 Oct; 22(10):1204-12. PubMed ID: 11110231
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase inhibitors in corneal endothelial transport.
Malikowski TM; Bosch JB; Min S; Duffey ME; Patel SP
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2652-8. PubMed ID: 24667858
[TBL] [Abstract][Full Text] [Related]
7. Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.
Pinard MA; Boone CD; Rife BD; Supuran CT; McKenna R
Bioorg Med Chem; 2013 Nov; 21(22):7210-5. PubMed ID: 24090602
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.
Rouland JF; Le Pen C; Gouveia Pinto C; Berto P; Berdeaux G
Pharmacoeconomics; 2003; 21(3):201-13. PubMed ID: 12558470
[TBL] [Abstract][Full Text] [Related]
9. In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common "diuretic and masking agent" in doping.
Busardò FP; Lo Faro AF; Sirignano A; Giorgetti R; Carlier J
Arch Toxicol; 2022 Jul; 96(7):1989-2001. PubMed ID: 35410394
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Sugrue MF
Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
[TBL] [Abstract][Full Text] [Related]
11. Dorzolamide-induced relaxation of intraocular porcine ciliary arteries in vitro depends on nitric oxide and the vascular endothelium.
Kringelholt S; Simonsen U; Bek T
Curr Eye Res; 2012 Dec; 37(12):1107-13. PubMed ID: 22816608
[TBL] [Abstract][Full Text] [Related]
12. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group.
Silver LH
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S141-5. PubMed ID: 10665516
[TBL] [Abstract][Full Text] [Related]
13. Toxic Epidermal Necrolysis Induced by the Topical Carbonic Anhydrase Inhibitors Brinzolamide and Dorzolamide.
Chun JS; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
Ann Dermatol; 2008 Dec; 20(4):260-2. PubMed ID: 27303208
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.
Sall K
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S155-62. PubMed ID: 10665518
[TBL] [Abstract][Full Text] [Related]
15. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
16. GC-NICI-MS analysis of acetazolamide and other sulfonamide (R-SO
Begou O; Drabert K; Theodoridis G; Tsikas D
J Pharm Anal; 2020 Feb; 10(1):49-59. PubMed ID: 32123599
[TBL] [Abstract][Full Text] [Related]
17. Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.
Cvetkovic RS; Perry CM
Drugs Aging; 2003; 20(12):919-47. PubMed ID: 14565787
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma.
Siesky B; Harris A; Cantor LB; Kagemann L; Weitzman Y; McCranor L; Marques C; Werne A; Stefansson E
Br J Ophthalmol; 2008 Apr; 92(4):500-4. PubMed ID: 18369067
[TBL] [Abstract][Full Text] [Related]
20. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes.
Ingram CJ; Brubaker RF
Am J Ophthalmol; 1999 Sep; 128(3):292-6. PubMed ID: 10511022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
